A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4
Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
Baseline to Week 4
Richard Finkelman, DDS, PhD
United States: Food and Drug Administration
|Research Site||Anaheim, California|
|Research Site||Danbury, Connecticut|
|Research Site||Boca Raton, Florida|
|Research Site||Baltimore, Maryland|
|Research Site||Battle Kreek, Michigan|
|Research Site||Albany, New York|
|Research Site||Asheville, North Carolina|
|Research Site||Allentown, Pennsylvania|